The opportunity of patient-journey studies for academic clinical research in oncology.

ABSTRACT: A wave of new treatments and treatment combinations are becoming available for solid tumours. Trials performed to obtain registration establish a positive benefit-risk but unavoidably leave many questions unanswered on place-in-therapy and the relative efficacy of different treatment sequences. Such limitations create problems in terms of strength of treatment guidelines and reimbursement (in countries where a public payer exists). Data on new drugs arriving during the last 10 years for the treatment of hepatocellular carcinoma and renal cancer are reported as an example of how the fortunate condition of having new effective treatments may translate into uncertainty regarding the optimal treatment plan. We suggest that academic research should react to such limitations and propose a model

SUBMITTER: Perrone F 

PROVIDER: S-EPMC8461282 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature